Gapping down
In reaction to disappointing earnings/guidance:
- SDC -23%, RVLV -18.7%, SUPN -17.3% (also announces SPN-810 trial did not meet primary endpoint), VICR -13.2%, FOSL -12.4%, PODD -11.6%, TOL -10.5%, SCCO -9.3%, WB -9.2%, PLNT -8.3%, SINA -7.8%, EXEL -7.2% (also announces enrollment of first 100 patients in COSMIC-311), ATRO -7.2%, GWPH -6.7%, PEN -6.7%, SPCE -6.5%, REAL -6.5%, UIS -6.3%, OSW -5.7%, WEN -4.6%, UTHR -4.3%, DAKT -3.9%, SSYS -3.8%, ORA -3.7%, RYAM -3.7%, INGN -3.5%, TPB -3.3%, JAZZ -2.9%, EVTC -2.7%, CRM -2.6% (also Keith Block will step down as co-CEO; also to acquire Vlocity), DK -2%, DY -1.8%, AMRN -1.7%, PEI -1.7%, RRGB -1.3%, MGPI -1.3%, CIO -1.1%, LDL -0.9%
Other news:
- VNDA -7.6% (announces results from Phase III EPIONE study of tradipitant for the treatment of pruritus in atopic dermatitis; the study did not meet is primary endpoint across the overall study population)
- TSLA -3.3% (Panasonic will exit solar cell production at Tesla's New York plant)
- DIS -2.2% (CEO Bob Iger steps down; Bob Chapek new CEO)
- UBER -1.6% (Jason Droege, head of the Uber Eats business, will be leaving)
- FRPT -0.7% (announces stock offering)
Analyst comments:
- KBH -5.2% (downgraded to Hold from Buy at SunTrust)
- DHI -3.2% (downgraded to Hold from Buy at SunTrust)
- KOS -2.4% (downgraded to Mkt Perform from Outperform at Bernstein)
- NKE -1.4% (downgraded to Hold from Buy at HSBC Securities)
- AOS -1.1% (downgraded to Neutral from Outperform at Robert W. Baird)
- PHM -0.8% (downgraded to Hold from Buy at SunTrust)